腎臓病治療薬の世界市場

腎臓病治療薬の世界市場は2030年までに219億米ドルに達する見込み

2024年に167億米ドルと推定される腎臓病治療薬の世界市場は、2024年から2030年にかけてCAGR 4.6%で成長し、2030年には219億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである経口投与は、CAGR 4.0%を記録し、分析期間終了時には127億米ドルに達すると予測されます。非経口投与セグメントの成長率は、分析期間中CAGR 5.3%と推定されます。

米国市場は45億米ドルと推定、中国はCAGR 7.2％で成長予測

米国の腎臓病治療薬市場は2024年に45億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに43億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.3%と4.6%と予測されています。欧州では、ドイツがCAGR 2.9%で成長すると予測されています。

世界の腎臓病治療薬市場- 主要動向と促進要因のまとめ

なぜ腎臓病治療薬は腎臓関連疾患の世界の負担増を管理する上で重要なのか？

慢性腎臓病（CKD）、急性腎障害（AKI）、糸球体腎炎、ネフローゼ症候群、末期腎臓病（ESRD）など、腎機能に影響を及ぼす疾患を対象とした腎臓病治療薬は、腎臓関連の健康負担の世界の広がりに対応するために注目を集めています。国際腎臓学会によれば、世界中で8億5,000万人以上が腎臓病に罹患しており、薬理学的介入は病気の進行を遅らせ、合併症を最小限に抑え、患者のQOLを向上させる上で中心的なものとなっています。

その主な要因としては、糖尿病、高血圧、肥満、高齢化などの急激な増加が挙げられ、これらはすべて腎臓のリスクを著しく高める。さらに、腎臓の合併症は発見が遅れることが多く、機能を安定させ透析や移植を防ぐために積極的な薬物療法が必要となります。その治療法は、降圧剤（ACE阻害剤、ARB）、赤血球造血刺激因子製剤（ESA）、リン酸結合剤、カリウム結合剤、ナトリウム-グルコース共輸送体2（SGLT2）阻害剤、免疫抑制剤など多岐にわたる。腎臓内科はプライマリ・ケアと専門医療の両方と交差しているため、この領域における薬剤革新は、心臓代謝や免疫学的領域へと拡大しています。

治療イノベーションと腎臓に特化した薬剤設計は、疾患管理をどのように変革しているか？

腎臓内科の治療状況は、対症療法から疾患修飾アプローチへと変化しており、その原動力となっているのが、腎臓病態に特化した薬剤革新です。SGLT2阻害薬は当初2型糖尿病治療薬として承認されたが、腎保護作用を示し、CKDの進行を遅らせ、腎機能が低下した患者の心不全による入院率を減少させました。非ステロイド性ミネラルコルチコイド受容体拮抗薬（MRA）であるファインレノンは、糖尿病性腎疾患においてアルブミン尿を減少させ、ESRDを遅らせることが示されたもう一つの画期的な治療薬です。

生物学的製剤や標的免疫抑制剤も、ループス腎炎、巣状分節性糸球体硬化症（FSGS）、IgA腎症などの糸球体疾患に対して開発されています。ベリムマブやボクロスポリンなどのモノクローナル抗体は自己免疫性腎症の治療選択肢を広げています。精密投与アルゴリズム、腎薬理ゲノミクス、腎クリアランスの減少に合わせたドラッグデリバリーシステムは、CKDの病期を問わず、より安全で効果的な治療を可能にしています。このような開発により、腎臓学は消極的治療から積極的な臓器温存治療へと移行しつつあります。

どのような患者集団と地域のヘルスケアシステムが腎臓内科治療薬の需要を形成しているか？

腎臓病治療薬を必要とする最大の患者集団は、糖尿病、高血圧、加齢に伴う腎機能低下です。CKDは、特に米国、南アジア、アフリカの一部で、スクリーニングや早期介入へのアクセスが制限されている高齢者や有色人種に不釣り合いに影響を及ぼしています。世界の透析人口は今後10年間で500万人を超えると予測されており、貧血管理薬、リン酸塩調整薬、カリウム安定化薬に対する継続的な需要も牽引しています。

北米は、高い透析人口、成熟した透析インフラ、専門医へのアクセスの普及を背景に、市場をリードしています。欧州は、統合された腎治療パスウェイとSGLT2阻害薬の普及により、僅差で続いています。アジア太平洋は、糖尿病性腎症の罹患率の高さ、未診断人口の多さ、償還制度の進化により、最も急速に成長しています。インド、中国、日本では、疾患罹患率の上昇と腎治療薬への現地製薬企業の投資の両方が見られます。ラテンアメリカと中東は新興市場で、都市化と非感染性疾患の蔓延が腎臓病治療薬の普及を加速させています。

腎臓病治療薬市場の長期的成長と革新の原動力は？

腎臓病治療薬市場の成長の原動力は、世界人口の高齢化、糖尿病や心血管疾患などの合併症の増加、透析や移植への依存を防ぐという臨床的緊急性です。世界の医療政策は、CKDスクリーニング、バイオマーカーによる層別化、早期薬理学的介入を重視しており、一次医療から三次医療まで腎臓病治療薬の役割を強化しています。腎臓専門医、内分泌専門医、循環器専門医による共同ケアモデルは、統合処方をさらに後押ししています。

線維症、炎症、内皮機能障害を標的とした新規薬剤により、パイプラインの技術革新が加速しています。製薬会社と腎臓研究ネットワークとの提携により、迅速な臨床試験、実データ解析、バイオマーカーの検証が可能になっています。eGFRモニタリングアプリやAIを活用した腎症リスクカリキュレーターなどのデジタルヘルスツールは、個別化治療や服薬アドヒアランスをサポートしています。CKDが世界の健康課題の上位に位置する中、腎臓病治療薬は、腎保護だけでなく、心臓-腎臓-代謝軸にわたる全身的な利益を提供する、不可欠な存在であり続けると思われます。

セグメント

投与経路（経口、非経口、その他の投与経路）、薬剤クラス（ACE阻害薬、アンジオテンシン受容体拮抗薬、B遮断薬、カルシウム拮抗薬、ループ利尿薬、赤血球造血刺激因子製剤、リン酸結合剤、その他の薬剤クラス）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（全41件）

• AbbVie Inc.
• Akebia Therapeutics, Inc.
• Alexion Pharmaceuticals
• Amgen Inc.
• AstraZeneca plc
• Baxter International Inc.
• Biocon Limited
• CSL Vifor
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche AG
• FibroGen, Inc.
• Fresenius Medical Care AG & Co. KGaA
• GlaxoSmithKline plc（GSK）
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Zydus Lifesciences Limited

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Nephrology Drugs Market to Reach US$21.9 Billion by 2030

The global market for Nephrology Drugs estimated at US$16.7 Billion in the year 2024, is expected to reach US$21.9 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Oral Administration, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$12.7 Billion by the end of the analysis period. Growth in the Parenteral Administration segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.5 Billion While China is Forecast to Grow at 7.2% CAGR

The Nephrology Drugs market in the U.S. is estimated at US$4.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.3 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Nephrology Drugs Market - Key Trends & Drivers Summarized

Why Are Nephrology Drugs Critical in Managing the Rising Global Burden of Kidney-Related Disorders?

Nephrology drugs, which target conditions affecting renal function-including chronic kidney disease (CKD), acute kidney injury (AKI), glomerulonephritis, nephrotic syndrome, and end-stage renal disease (ESRD)-are gaining prominence in response to the growing global prevalence of kidney-related health burdens. With over 850 million people worldwide affected by kidney diseases, according to the International Society of Nephrology, pharmacological intervention has become central to delaying disease progression, minimizing complications, and improving patient quality of life.

Key drivers include the rapid rise in diabetes, hypertension, obesity, and aging populations-all of which significantly elevate renal risk. Moreover, kidney complications are often detected late, necessitating aggressive pharmacological management to stabilize function and prevent dialysis or transplantation. Therapies span a wide range, including antihypertensives (ACE inhibitors, ARBs), erythropoiesis-stimulating agents (ESAs), phosphate binders, potassium binders, sodium-glucose co-transporter 2 (SGLT2) inhibitors, and immunosuppressants. With nephrology intersecting both primary care and specialty medicine, drug innovation in this space is expanding into cardiometabolic and immunological domains.

How Are Therapeutic Innovations and Renal-Specific Drug Designs Transforming Disease Management?

The therapeutic landscape for nephrology is shifting from symptom management to disease-modifying approaches, driven by drug innovations that specifically target renal pathology. SGLT2 inhibitors, initially approved for type 2 diabetes, have demonstrated renal protective effects, slowing progression of CKD and reducing hospitalization rates for heart failure in patients with impaired renal function. Finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), is another breakthrough therapy shown to reduce albuminuria and delay ESRD in diabetic kidney disease.

Biologics and targeted immunosuppressants are also being developed for glomerular diseases such as lupus nephritis, focal segmental glomerulosclerosis (FSGS), and IgA nephropathy. Monoclonal antibodies like belimumab and voclosporin are expanding treatment options in autoimmune nephropathies. Precision dosing algorithms, renal pharmacogenomics, and drug delivery systems tailored for reduced renal clearance are enabling safer and more effective therapy across CKD stages. These developments are shifting nephrology from reactive treatment to proactive, organ-preserving care.

Which Patient Populations and Regional Healthcare Systems Are Shaping Demand for Nephrology Therapeutics?

The largest patient cohorts requiring nephrology drugs are those with diabetes, hypertension, and aging-related renal function decline. CKD disproportionately affects older adults and people of color, particularly in the U.S., South Asia, and parts of Africa where access to screening and early intervention remains limited. The global dialysis population-projected to surpass 5 million in the next decade-also drives ongoing demand for anemia management, phosphate regulation, and potassium stabilization drugs.

North America is the leading market, driven by high disease prevalence, mature dialysis infrastructure, and widespread access to specialist care. Europe follows closely with integrated renal care pathways and widespread adoption of SGLT2 inhibitors. Asia-Pacific is experiencing the fastest growth due to high rates of diabetic nephropathy, large undiagnosed populations, and evolving reimbursement frameworks. India, China, and Japan are witnessing both rising disease incidence and local pharmaceutical investment in renal therapeutics. Latin America and the Middle East are emerging markets, where urbanization and non-communicable disease prevalence are accelerating nephrology drug uptake.

What Is Fueling Long-Term Growth and Innovation in the Nephrology Drugs Market?

The growth in the nephrology drugs market is fueled by an aging global population, increasing incidence of comorbidities such as diabetes and cardiovascular disease, and the clinical urgency of preventing dialysis and transplant dependence. Global health policy is emphasizing CKD screening, biomarker-driven stratification, and early pharmacological intervention, reinforcing the role of nephrology drugs across primary and tertiary care. Collaborative care models between nephrologists, endocrinologists, and cardiologists are further boosting integrated prescribing.

Pipeline innovation is accelerating with novel agents targeting fibrosis, inflammation, and endothelial dysfunction. Partnerships between pharma firms and renal research networks are enabling rapid clinical trials, real-world data analysis, and biomarker validation. Digital health tools, including eGFR monitoring apps and AI-driven nephropathy risk calculators, are supporting personalized therapy and medication adherence. As CKD moves up the global health agenda, nephrology drugs will remain indispensable-delivering not only renal protection but systemic benefits across the heart-kidney-metabolic axis.

SCOPE OF STUDY:

The report analyzes the Nephrology Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Oral, Parenteral, Other Administration Routes); Drug Class (ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents, Phosphate Binders, Other Drug Classes); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• AbbVie Inc.
• Akebia Therapeutics, Inc.
• Alexion Pharmaceuticals
• Amgen Inc.
• AstraZeneca plc
• Baxter International Inc.
• Biocon Limited
• CSL Vifor
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche AG
• FibroGen, Inc.
• Fresenius Medical Care AG & Co. KGaA
• GlaxoSmithKline plc (GSK)
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Zydus Lifesciences Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Nephrology Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Chronic Kidney Disease Spurs Demand for Nephrology Therapeutics
  • Expansion of Geriatric Population Globally Strengthens Business Case for Long-Term Nephrology Care
  • Increase in Diabetic and Hypertensive Patient Populations Drives Growth in Renal Drug Prescriptions
  • Launch of Next-Generation SGLT2 Inhibitors Throws the Spotlight on Renoprotective Drug Classes
  • Introduction of Non-Steroidal Mineralocorticoid Receptor Antagonists Expands Therapeutic Options
  • Regulatory Approvals of First-In-Class Therapies Accelerate Adoption of Innovative Renal Treatments
  • Surge in Dialysis-Associated Complications Generates Demand for Adjunct Nephrology Therapies
  • Expansion of CKD Clinical Management Guidelines Propels Adoption of Early-Stage Interventions
  • Growing Emphasis on Cardiovascular-Renal Drug Synergies Enhances Combination Therapy Utilization
  • Adoption of AI-Driven Risk Stratification Tools Supports Personalized Nephrology Drug Regimens
  • Increasing Access to Nephrology Services in Emerging Markets Expands Addressable Patient Base
  • Heightened Focus on Patient Adherence and Quality-of-Life Outcomes Drives Long-Acting Formulations
  • Rising Investments in Rare Kidney Disorder Research Spurs Orphan Drug Development
  • Integration of Biomarkers in Kidney Function Monitoring Enhances Drug Efficacy Targeting
  • Growth in Renal Transplant Cases Strengthens Demand for Post-Operative Nephrology Drugs
  • Challenges in Reimbursement and Therapy Affordability Create Market Access Barriers
  • Improved Diagnostic Screening Rates for Early Kidney Disease Spur Preventive Treatment Adoption
  • Availability of Biosimilars for Renal Anemia Management Expands Cost-Effective Treatment Access
  • Digital Patient Monitoring in CKD Care Pathways Supports Therapy Optimization
  • Global Harmonization of Renal Drug Trial Protocols Facilitates Multinational R&D
  • Expansion of Home Dialysis Trends Reinforces Need for Supportive Nephrology Pharmacotherapy
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Nephrology Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Nephrology Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Nephrology Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Nephrology Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for ACE Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Angiotensin Receptor Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Angiotensin Receptor Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Angiotensin Receptor Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for B-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for B-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for B-Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Loop Diuretics Erythropoiesis-Stimulating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Loop Diuretics Erythropoiesis-Stimulating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Loop Diuretics Erythropoiesis-Stimulating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Phosphate Binders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Phosphate Binders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Phosphate Binders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 44: USA Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• JAPAN
  • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• CHINA
  • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 71: China Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• EUROPE
  • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Nephrology Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Nephrology Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Nephrology Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• FRANCE
  • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 92: France Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• GERMANY
  • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 119: UK Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Nephrology Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Nephrology Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Nephrology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• INDIA
  • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 176: India Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Nephrology Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Nephrology Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Nephrology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Nephrology Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Nephrology Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Nephrology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
• AFRICA
  • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030

IV. COMPETITION